Parkinson's Disease
43 competing products in clinical development for Parkinson's Disease.
Pipeline by Phase
Phase 16
Phase 218
Phase 2/31
Phase 316
Approved2
All Products (43)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Lemborexant + placebo | Eisai | Approved | Recruiting | 50 |
| Mirabegron + Placebo | Astellas Pharma | Approved | Completed | 43 |
| E2007 | Eisai | Phase 3 | Completed | 40 |
| Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo | Eisai | Phase 3 | Completed | 40 |
| 2 mg perampanel + 4 mg perampanel + placebo comparator | Eisai | Phase 3 | Completed | 40 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 3 | Completed | 40 |
| KW-6500 | Kyowa Kirin | Phase 3 | Completed | 40 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 3 | Completed | 40 |
| Istradefylline | Kyowa Kirin | Phase 3 | Completed | 40 |
| Istradefylline + Istradefylline + Placebo | Kyowa Kirin | Phase 3 | Completed | 40 |
| KW-6500 + KW-6500 Placebo | Kyowa Kirin | Phase 3 | Completed | 40 |
| Istradefylline ( KW-6002) | Kyowa Kirin | Phase 3 | Completed | 40 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 3 | Completed | 40 |
| KW-6500 | Kyowa Kirin | Phase 3 | Completed | 40 |
| istradefylline | Kyowa Kirin | Phase 2/3 | Completed | 38 |
| piclozotan + 0.9% sodium chloride (normal saline) | Daiichi Sankyo | Phase 2 | Completed | 35 |
| GPI 1485 | Eisai | Phase 2 | Completed | 35 |
| E2007 + E2007 + E2007 | Eisai | Phase 2 | Completed | 35 |
| E2007 | Eisai | Phase 2 | Completed | 35 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 2 | Completed | 35 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 2 | Completed | 35 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 2 | Completed | 35 |
| KW-6356 + Placebo | Kyowa Kirin | Phase 2 | Completed | 35 |
| KW-6356 + KW-6356 + Placebo | Kyowa Kirin | Phase 2 | Completed | 35 |
| Istradefylline (KW-6002) | Kyowa Kirin | Phase 2 | Completed | 35 |
| KW-6002 (istradefylline) | Kyowa Kirin | Phase 2 | Completed | 35 |
| apomorphine hydrochloride | Kyowa Kirin | Phase 2 | Completed | 35 |
| Istradefylline + Istradefylline + Placebo | Kyowa Kirin | Phase 2 | Completed | 35 |
| ONO-2506PO | Ono Pharmaceutical | Phase 2 | Completed | 35 |
| E2007 | Eisai | Phase 3 | Terminated | 32 |
| Perampanel | Eisai | Phase 3 | Terminated | 32 |
| Placebo + E2007 + E2007 | Eisai | Phase 3 | Terminated | 32 |
| Istradefylline | Kyowa Kirin | Phase 3 | Terminated | 32 |
| Istradefylline 40 mg + Rifampin 300mg BID + istradefylline 40mg Day 8 only | Kyowa Kirin | Phase 1 | Completed | 29 |
| KW-6356 + Clarithromycin + Rifampicin | Kyowa Kirin | Phase 1 | Completed | 29 |
| Midazolam + Caffeine + Rosuvastatin + KW-6356 | Kyowa Kirin | Phase 1 | Completed | 29 |
| KW-6356 + KW-6356 + Placebo + Moxifloxacin | Kyowa Kirin | Phase 1 | Completed | 29 |
| KW-6356 Low Dose + KW-6356 Middle Dose + KW-6356 High Dose + KW-6356 X Dose + KW-6356 Y Dose + Placebo | Kyowa Kirin | Phase 1 | Completed | 29 |
| perampanel + placebo | Eisai | Phase 2 | Terminated | 27 |
| E2007 | Eisai | Phase 2 | Terminated | 27 |
| E2007 | Eisai | Phase 2 | Withdrawn | 27 |
| Perampanel | Eisai | Phase 2 | Terminated | 27 |
| UB-312 + Placebo | Vaxxinity | Phase 1 | Completed | 19 |